TransThera Biosciences Co. Ltd
http://www.transtherabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TransThera Biosciences Co. Ltd
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Korea Gains Speed In Race For NASH Therapies
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.
Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Nanjing Transtherabio Sciences Co. Ltd.
- Nanjing TransThera Biosciences Co. Ltd.